- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Community-acquired Pneumonia AND Lobar Pneumonia.
Displaying page 1 of 1.
EudraCT Number: 2007-001735-66 | Sponsor Protocol Number: NXL103/2001 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:Novexel S. A. | |||||||||||||
Full Title: A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL... | |||||||||||||
Medical condition: Community-Acquired Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003971-20 | Sponsor Protocol Number: CE01-300 | Start Date*: 2013-05-07 | |||||||||||
Sponsor Name:Cempra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Ac... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) PL (Completed) LV (Completed) EE (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003026-14 | Sponsor Protocol Number: ML-3341-306 | Start Date*: 2016-02-04 | |||||||||||
Sponsor Name:Melinta Therapeutics, Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTE... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) LV (Completed) BG (Completed) DE (Completed) SI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003453-13 | Sponsor Protocol Number: CE01-301 | Start Date*: 2014-06-18 | |||||||||||
Sponsor Name:Cempra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Ad... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) LV (Completed) DE (Completed) ES (Completed) RO (Completed) SK (Completed) NL (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002203-18 | Sponsor Protocol Number: P903-31 | Start Date*: 2012-07-18 | ||||||||||||||||||||||||||
Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories) | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With... | ||||||||||||||||||||||||||||
Medical condition: Community-acquired Bacterial Pneumonia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002683-32 | Sponsor Protocol Number: DUR001-305 | Start Date*: 2015-03-30 | |||||||||||
Sponsor Name:Durata Therapeutics International B.V. | |||||||||||||
Full Title: A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia | |||||||||||||
Medical condition: Community acquired bacterial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000736-37 | Sponsor Protocol Number: 1001 | Start Date*: 2022-08-12 | ||||||||||||||||
Sponsor Name:Biotest AG | ||||||||||||||||||
Full Title: A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneu... | ||||||||||||||||||
Medical condition: non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) ES (Prematurely Ended) HU (Completed) AT (Ongoing) BE (Ongoing) LV (Ongoing) LT (Ongoing) PT (Ongoing) SK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004039-37 | Sponsor Protocol Number: CE01-203 | Start Date*: 2014-10-10 |
Sponsor Name:Cempra Pharmaceuticals, Inc. | ||
Full Title: A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients ... | ||
Medical condition: suspected or confirmed community acquired bacterial pneuumonia (CABP) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA GB (Completed) HU (Completed) ES (Temporarily Halted) | ||
Trial results: View results |
EudraCT Number: 2004-002798-21 | Sponsor Protocol Number: WI18273 | Start Date*: 2005-02-18 |
Sponsor Name:F.Hoffmann-La Roche Ltd | ||
Full Title: A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitaliza... | ||
Medical condition: Community-acquired pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) SK (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016069-27 | Sponsor Protocol Number: DORIPED3003 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | |||||||||||||
Medical condition: Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021574-11 | Sponsor Protocol Number: 32729463CAP2001 | Start Date*: 2011-01-24 | |||||||||||
Sponsor Name:Furiex Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospita... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia (CABP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004782-92 | Sponsor Protocol Number: NAB-BC-3781-3102 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia | |||||||||||||
Medical condition: Community-acquired bacterial pneumonia (CABP) is a commonly occurring serious infection that requires systemic antibiotic therapy and is associated with substantial morbidity, mortality, and consid... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005169-63 | Sponsor Protocol Number: NAB-BC-3781-3101 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) LV (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005097-25 | Sponsor Protocol Number: KIDS-STEP | Start Date*: Information not available in EudraCT |
Sponsor Name:Universitätskinderspital beider Basel (UKBB) | ||
Full Title: A randomised placebo-controlled multi-centre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community acquired pneumonia (CAP) | ||
Medical condition: Children with community acquired pneumonia (CAP). | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000809-36 | Sponsor Protocol Number: CAP-IT | Start Date*: 2016-09-30 |
Sponsor Name:Medical Research Council Clinical Trials Unit at UCL | ||
Full Title: Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial. | ||
Medical condition: Pneumonia | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002479-28 | Sponsor Protocol Number: MOL-ARDS-002 | Start Date*: 2015-09-24 | |||||||||||
Sponsor Name:Justus-Liebig University | |||||||||||||
Full Title: GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration | |||||||||||||
Medical condition: Pneumonia associated Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.